Clinical worsening in trials of pulmonary arterial hypertension: results and implications
The DOI matches its Crossref record.
Abstract
PURPOSE OF REVIEW: Time to clinical worsening (TTCW) can be used to assess disease progression associated with pulmonary arterial hypertension (PAH). As a consequence, it is highly relevant to patients, clinicians, and regulatory agencies. The majority of clinical trials of PAH-specific drug therapies have included TTCW as a secondary endpoint; this article summarizes the results of randomized controlled clinical trials in PAH, specifically with respect to the clinical worsening endpoint. RECENT FINDINGS: Some trials have demonstrated a treatment-related delay in TTCW and others have not. Recent results suggest that TTCW shows particular promise in detecting disease progression, even in mildly affected patients. Definitions of clinical worsening have also varied across clinical trials; although all have agreed on the inclusion of all-cause death and hospitalization due to PAH in the definition, the inclusion of additional parameters defining 'disease progression' has differed. SUMMARY: There is a need for a clear and uniform definition of TTCW that can be tailored to the study population being investigated; the endpoint may require adaptation for patients in different functional classes and with different causes. Consistency of event reporting within a trial may be improved by employing a committee to adjudicate events. Trials are beginning to include TTCW as a primary endpoint; the results will be important in establishing the validity of whether this parameter should become the endpoint of choice in PAH trials in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,443
Self-citationRiociguat for the treatment of pulmonary arterial hypertension
Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209655 · Cited by 1,346
“Associated with connective-tissue disease 25 (20) 71 (28) 15 (24) 111 (25)”
Self-citationFrost, A. E., Badesch, D. B., Miller, D. P., Benza, R. L., Meltzer, L. A., & McGoon, M. D. (2013) · Chest · doi:10.1378/chest.12-3023 · Cited by 90
Self-citationDingemanse, J., Sidharta, P. N., Maddrey, W. C., Rubin, L. J., & Mickail, H. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.859674 · Cited by 75
Self-citation
Metadata
- Authors
- Galiè, N., Simonneau, G., Barst, R. J., Badesch, D., & Rubin, L.
- Venue
- Current Opinion in Pulmonary Medicine
- Published
- 2010-05
- Volume
- 16
- Issue
- Suppl 1
- Pages
- S11-S19
- ISSN
- 1070-5287 (ISSN-L)
- OpenAlex
- W2140029513
- Cited by
- 41
- References
- 0
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical worsening in trials of pulmonary arterial hypertension: results and implications. https://app.cochat.ai/papers/10.1097/01.mcp.0000370206.61003.7e
- The paper
- Galiè, N., Simonneau, G., Barst, R. J., Badesch, D., & Rubin, L. (2010). Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Current Opinion in Pulmonary Medicine. https://doi.org/10.1097/01.mcp.0000370206.61003.7e
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.